Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H. Barouch, Ludo Lavreys, Joseph P. Nkolola et al.|The Lancet|2018Cited by 342
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S. Li, Daniel E. Geraghty, Peter B. Gilbert et al.|Journal of Clinical Investigation|2014Cited by 109
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisitionHeather A. Prentice, Rasmi Thomas, Georgia D. Tomaras et al.|Science Translational Medicine|2015Cited by 54
An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccinationJuan Manuel Carreño, Florian Krammer, Ariel Raskin et al.|Science Translational Medicine|2023Cited by 23